101
EDE approves new RINVOQ use as first oral treatment for non-segmental vitiligo
19.08.2026
The Emirates Drug Establishment (EDE) has approved a new therapeutic indication for RINVOQ (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 years and older whose condition requires systemic therapy through medicines that circulate in the bloodstream, making it the first licensed oral treatment for this group of patients.
